Financing to Expand U.S. Commercial Introduction and Manufacturing
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the $13 billion global dialysis market, today announced $76.5 million in Series C equity funding. A new investor, funds advised by T. Rowe Price Associates, Inc., led the round, which also included participation from existing investors Fidelity Management & Research Company, Partner Fund Management LP, Warburg Pincus, Perceptive Advisors and The Vertical Group.
Outset’s technology, the Tablo™ Hemodialysis System, is the first novel dialysis system to reach the U.S. market in more than 15 years. The system can be used flexibly across a range of clinical settings from dialysis clinics to hospitals and skilled nursing facilities. The company will use proceeds from the financing to expand the commercial introduction of the Tablo System in acute and chronic care markets in the United States.
Read More: http://www.businesswire.com/news/home/20170503005383/en/Outset-Medical-Announces-76.5-Million-Funding-Innovative
Via: Business Wire